Tamoxifen Interactions

Do not use in combination with anastrozole. Co-administration reduced anastrozole plasma concentration by 27% and showed no efficacy benefit over tamoxifen monotherapy.

Source: NLP:anastrozole

Do not use in combination with anastrozole tablets. Co-administration reduced anastrozole plasma concentration by 27% and showed no efficacy benefit over tamoxifen monotherapy.

Source: NLP:anastrozole tablets

Concomitant use of chloroquine with tamoxifen is not recommended due to risk of retinal toxicity.

Source: NLP:chloroquine phosphate

Concomitant use may increase the risk of thromboembolic complications when used with cyclophosphamide-containing chemotherapy regimen.

Source: NLP:cyclophosphamide

Binds to estrogen receptor and competes with fluoroestradiol F 18, reducing detection of ER-positive lesions. Discontinue for at least 8 weeks before administering CERIANNA.

Source: NLP:fluoroestradiol f 18

Paroxetine's CYP2D6 inhibition may reduce tamoxifen efficacy. Consider alternative antidepressant with little or no CYP2D6 inhibition.

Source: NLP:paroxetine

Consider alternative antidepressant with little or no CYP2D6 inhibition due to paroxetine's effect on tamoxifen metabolism.

Source: NLP:paroxetine hydrochloride hemihydrate

Bexarotene decreased tamoxifen plasma concentrations by approximately 35%, possibly through CYP3A4 induction.

Source: NLP:bexarotene

Requires CYP2D6 activation for efficacy. Bupropion's CYP2D6 inhibition may reduce tamoxifen efficacy, potentially requiring increased doses.

Source: NLP:bupropion hcl er (xl)

MultiHance may compete for MOAT transporter and prolong systemic exposure of tamoxifen.

Source: NLP:gadobenate dimeglumine

Coadministration reduces letrozole plasma levels by 38% on average, but clinical experience indicates therapeutic effect is not impaired when letrozole is administered immediately after tamoxifen.

Source: NLP:letrozole

Coadministration reduces letrozole plasma levels by 38% on average, but clinical experience indicates therapeutic effect of letrozole is not impaired when administered immediately after tamoxifen.

Source: NLP:letrozole tablets

May increase serum thyroxine-binding globulin concentration, resulting in initial transient increase in FT4 followed by decreased serum T4.

Source: NLP:levothyroxine sodium

May increase serum thyroxine-binding globulin concentration, altering T3 serum transport. Closely monitor thyroid hormone parameters.

Source: NLP:liothyronine sodium

No interaction observed between oral tamoxifen (30 mg) and intravenous ibandronate (2 mg).

Source: NLP:ibandronate sodium